Although this possibility has not been investigated, differential expression in the target, such as hormonal receptors in immune cells and major hormone-mediated signaling pathways [109,138], might result in reduced individual variations during pregnancy with more pronounced inhibitory effects in MS mothers. This evidence concerns the gene NR4A1 and myeloid sarcoma.